Incyte closes $1.25B Vega acquisition, adds Phase 3 bleeding-disorder drug VGA039

Filed July 6, 2026 · Period ending July 6, 2026 · ~1 min read

Key Changes

• high

  Incyte paid $1.25B upfront for Vega Therapeutics, with up to $750M in sales milestones. The company will record the transaction as a one-time R&D expense in Q3 and full year 2026 results.

  Item 8.01 — Other Events verify on EDGAR →
• high

  The acquisition adds VGA039, a Phase 3 monoclonal antibody for von Willebrand disease with FDA Breakthrough Therapy, Fast Track, orphan drug and rare pediatric disease designations.

  Item 8.01 — Other Events verify on EDGAR →
• high

  VGA039 is in the Phase 3 VIVID-6 study evaluating once-monthly subcutaneous prophylaxis for all types of VWD. Current treatments require frequent intravenous infusions.

  Item 8.01 — Other Events verify on EDGAR →